Two senior management appointments at Biogen Idec
This article was originally published in Scrip
Biogen Idec has named Dr Douglas Williams executive vice-president of R&D and Steven Holtzman executive vice-president of corporate development. Dr Williams will oversee global R&D, including discovery research, development, clinical operations and regulatory affairs, while Mr Holtzman will oversee corporate strategy, business development, portfolio management, programme leadership and the new ventures fund. Dr Williams has more than 20 years' scientific and leadership experience, having most recently served as CEO of ZymoGenetics. Mr Holtzman, who also has more than 20 years' industry experience, was previously founder, chairman and CEO of Infinity Pharmaceuticals. Both will report to Biogen Idec's CEO Dr George Scangos.